Lynx1 Capital Management’s C4 Therapeutics CCCC Stock Holding History

Lynx1 Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.2M	Buy	7,326,691 +327,789	+5%	+$1.12M	3.95%	5
2026 Q1	$18.4M	Sell	6,998,902 -99,231	-1%	-$234K	2.91%	6
2025 Q4	$13.6M	Hold	7,098,133	–	–	2.74%	5
2025 Q3	$15.8M	Hold	7,098,133	–	–	3.21%	6
2025 Q2	$10.2M	Hold	7,098,133	–	–	2.93%	8
2025 Q1	$11.4M	Buy	7,098,133 +245,389	+4%	+$732K	4.07%	7
2024 Q4	$24.7M	Sell	6,852,744 -27,783	-0.4%	-$138K	9.25%	4
2024 Q3	$39.2M	Hold	6,880,527	–	–	13.9%	3
2024 Q2	$31.8M	Buy	6,880,527 +3,245,865	+89%	+$19.4M	11.47%	4
2024 Q1	$29.7M	Buy	3,634,662 +500,266	+16%	+$3.88M	7.65%	7
2023 Q4	$17.7M	Buy	3,134,396 +2,115,166	+208%	+$4.82M	6.96%	5
2023 Q3	$1.9M	Buy	+1,019,230	New	+$3.11M	1.25%	13

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Lynx1 Capital Management's CCCC Position: Q2 2026 in Review

Lynx1 Capital Management increased its C4 Therapeutics (CCCC) stake by 4.7% in Q2 2026, buying an estimated $1.12M and bringing the position to 7,326,691 shares worth $34.2M. The position accounts for 3.95% of the portfolio, ranked #5.

Lynx1 Capital Management first reported a position in CCCC in Q3 2023 and has held it in 12 quarters since. The position peaked at $39.2M in Q3 2024. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Lynx1 Capital Management held 7,326,691 shares of C4 Therapeutics worth $34.2M as of Q2 2026.
Lynx1 Capital Management bought 327,789 C4 Therapeutics shares in Q2 2026, an estimated $1.12M.
C4 Therapeutics made up 3.95% of Lynx1 Capital Management's portfolio in Q2 2026, its #5 holding.
Lynx1 Capital Management first reported a position in C4 Therapeutics in Q3 2023 and has held it in 12 quarters since.
Lynx1 Capital Management's C4 Therapeutics position peaked at $39.2M in Q3 2024.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.